LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 32

Search options

  1. Article ; Online: Percutaneous Vertebroplasty in a Patient with Chronic Back Pain Caused by Multiple Schmorl's Nodes: A Case Report.

    Park, Hyung-Joon / Jo, Hyun-Ji / Lee, Jaeeun / Choi, Sang-Sik / Lee, Chung-Hun

    Medicina (Kaunas, Lithuania)

    2023  Volume 59, Issue 10

    Abstract: Background and ... ...

    Abstract Background and Objectives
    MeSH term(s) Male ; Humans ; Middle Aged ; Prospective Studies ; Treatment Outcome ; Intervertebral Disc Displacement ; Back Pain ; Vertebroplasty ; Lumbar Vertebrae/surgery ; Spinal Fractures/complications ; Spinal Fractures/surgery
    Language English
    Publishing date 2023-10-16
    Publishing country Switzerland
    Document type Case Reports
    ZDB-ID 2188113-3
    ISSN 1648-9144 ; 1010-660X
    ISSN (online) 1648-9144
    ISSN 1010-660X
    DOI 10.3390/medicina59101839
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Expression of PD-L1 as a predictive marker of sensitivity to immune checkpoint inhibitors in patients with advanced biliary tract cancer.

    Kim, Hongsik / Kim, Ryul / Jo, Hyunji / Kim, Hye Ryeon / Hong, Joohyun / Ha, Sang Yun / Park, Joon Oh / Kim, Seung Tae

    Therapeutic advances in gastroenterology

    2022  Volume 15, Page(s) 17562848221117638

    Abstract: Background: Expression of programmed death-ligand 1 (PD-L1) has been reported to correlate with response to immune checkpoint inhibitors (ICIs) in various tumor types. However, there are few data on the role of PD-L1 expression as a predictive and ... ...

    Abstract Background: Expression of programmed death-ligand 1 (PD-L1) has been reported to correlate with response to immune checkpoint inhibitors (ICIs) in various tumor types. However, there are few data on the role of PD-L1 expression as a predictive and prognostic biomarker of sensitivity to ICIs in patients with advanced biliary tract cancer (BTC).
    Objectives: We evaluated the role of PD-L1 expression as a predictive and prognostic biomarker of response to ICIs in patients with advanced BTC.
    Design: We retrospectively analyzed data from 83 advanced BTC patients who received ICIs as second- or third-line treatment between February 2018 and April 2021.
    Methods: All patient data analysis included evaluation of PD-L1 expression by the combined positive score (CPS).
    Results: Among 83 patients, 56 (67.5%) had PD-L1 positivity (CPS ⩾ 1). The objective response rate (ORR) to ICIs was significantly higher in advanced BTC patients with PD-L1 expression compared to those without PD-L1 expression (17.8%
    Conclusions: The present study suggests that the expression of PD-L1 alone was not sufficient as a novel marker to select advanced BTC patients who might benefit from ICIs. Additional comprehensive studies of biomarkers that can assist in predicting BTC patient responses to pembrolizumab and/or nivolumab therapy are required.
    Language English
    Publishing date 2022-08-16
    Publishing country England
    Document type Journal Article
    ZDB-ID 2440710-0
    ISSN 1756-2848 ; 1756-283X
    ISSN (online) 1756-2848
    ISSN 1756-283X
    DOI 10.1177/17562848221117638
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Impact of COPD Treatment on Survival in Patients with Advanced Non-Small Cell Lung Cancer.

    Jo, Hyunji / Park, Sojung / Kim, Nam Eun / Park, So Young / Ryu, Yon Ju / Chang, Jung Hyun / Lee, Jin Hwa

    Journal of clinical medicine

    2022  Volume 11, Issue 9

    Abstract: Chronic obstructive pulmonary disease (COPD) is associated with a poor prognosis in patients with non-small cell lung cancer (NSCLC). However, the impact of COPD treatment on the survival of patients with advanced NSCLC remains uncertain. We ... ...

    Abstract Chronic obstructive pulmonary disease (COPD) is associated with a poor prognosis in patients with non-small cell lung cancer (NSCLC). However, the impact of COPD treatment on the survival of patients with advanced NSCLC remains uncertain. We retrospectively investigated COPD patients among patients newly diagnosed with advanced NSCLC between September 2005 and August 2019 at a university hospital. The clinical characteristics, lung function, and survival outcomes were analyzed and compared between patients who did and did not receive COPD treatment. Among 221 patients with advanced NSCLC and COPD, 124 patients received treatment for COPD and 97 patients did not receive treatment for COPD. Forced expiratory volume in 1 s (FEV1) % predicted value was greater in the no-treatment group than in the COPD treatment group (p < 0.001). The median overall survival (OS) of the treatment group was 10.7 months, while that of the no-treatment group was 8.7 months (p = 0.007). In the multivariate analysis, COPD treatment was independently associated with improved OS (hazard ratio 0.71, 95% confidence interval 0.53−0.95, and p = 0.021). COPD treatment was associated with improved OS in patients with advanced NSCLC and COPD. Therefore, pretreatment spirometry and maximal treatment for COPD may offer a chance of optimal management for patients with advanced NSCLC.
    Language English
    Publishing date 2022-04-24
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm11092391
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Role of upfront autologous stem cell transplantation in patients newly diagnosed with primary CNS lymphoma treated with R-MVP: real-world data from a retrospective single-center analysis.

    Yoon, Sang Eun / Jo, Hyunji / Kang, Eun-Suk / Cho, Duck / Cho, Junhun / Kim, Won Seog / Kim, Seok Jin

    Bone marrow transplantation

    2022  Volume 57, Issue 4, Page(s) 641–648

    Abstract: The role of upfront autologous stem cell transplantation (ASCT) remains unclear in patients with primary central nervous system lymphoma (PCNSL) receiving rituximab and high-dose methotrexate (MTX)-based chemotherapy. We analyzed the outcomes of upfront ... ...

    Abstract The role of upfront autologous stem cell transplantation (ASCT) remains unclear in patients with primary central nervous system lymphoma (PCNSL) receiving rituximab and high-dose methotrexate (MTX)-based chemotherapy. We analyzed the outcomes of upfront ASCT in 106 patients with PCNSL (median age, 64 years; range, 34-86) who received rituximab, MTX, vincristine, and prednisolone (R-MVP). The objective response rate was 88.7% (94/106) and included 46 complete responses (43.4%). Upfront ASCT was performed in 38 responders (median age, 51 years; range, 34-69), including 13 patients aged >60 years, after conditioning with busulfan (3.2 mg/kg, days 8 to 5) and thiotepa (5 mg/kg, days 4-3). For 56 responders ineligible for ASCT because of age >70 years, poor performance status, or refusal to undergo upfront ASCT, other consolidation treatments (n = 32) or observation (n = 24) were performed. With a median follow-up of 24.4 months (95% confidence interval, 20.7-28.0 months), no transplantation-related deaths occurred and seven patients relapsed after upfront ASCT. By contrast, 24 relapses occurred in patients who did not receive upfront ASCT. The progression-free and overall survival were significantly better in patients undergoing upfront ASCT (P = 0.001). Our real-world data suggest the benefit from upfront ASCT.
    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols ; Central Nervous System Neoplasms ; Combined Modality Therapy ; Hematopoietic Stem Cell Transplantation ; Humans ; Lymphoma/drug therapy ; Methotrexate ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy ; Retrospective Studies ; Rituximab/therapeutic use ; Transplantation, Autologous
    Chemical Substances Rituximab (4F4X42SYQ6) ; Methotrexate (YL5FZ2Y5U1)
    Language English
    Publishing date 2022-02-16
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 632854-4
    ISSN 1476-5365 ; 0268-3369 ; 0951-3078
    ISSN (online) 1476-5365
    ISSN 0268-3369 ; 0951-3078
    DOI 10.1038/s41409-022-01605-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Comprehensive comparison of international prognostic indexes for follicular helper T-cell lymphoma.

    Lee, Yong-Pyo / Yoon, Sang Eun / Cho, Junhun / Ko, Young Hyeh / Jo, Hyunji / Kim, Seok Jin / Kim, Won Seog

    Annals of hematology

    2022  Volume 101, Issue 7, Page(s) 1535–1543

    Abstract: In 2016, World Health Organization classification of lymphoid neoplasms separated firmly-follicular helper (Tfh) cell origin lymphomas from peripheral T-cell lymphoma-not specified (PTCL-NOS) based on their unique immunogenic characteristics. Generally, ... ...

    Abstract In 2016, World Health Organization classification of lymphoid neoplasms separated firmly-follicular helper (Tfh) cell origin lymphomas from peripheral T-cell lymphoma-not specified (PTCL-NOS) based on their unique immunogenic characteristics. Generally, Tfh cell origin lymphoma, which has an approximately 25% incidence, is classified into three categories: angioimmunoblastic T-cell lymphoma (AITL), follicular peripheral T-cell lymphoma (F-PTCL), and nodal peripheral T-cell lymphoma with a T-follicular helper phenotype (nodal PTCL with Tfh cell phenotype). Their prognosis has been estimated using four traditional prognostic tools for T-cell lymphoid malignancies: the international prognostic index (IPI), the prognostic index for peripheral T-cell lymphoma unspecified (PIT), the modified PIT (mPIT) and the international T-cell lymphoma project index. In addition, the AITL score that reflects AITL characteristics well has been introduced recently. However, there are no clear guidelines for evaluating the prognosis of Tfh cell lymphoma. Thus, we performed a comparative analysis to determine which of these five indexes is most suitable for Tfh cell lymphoma. We evaluated the accuracy of classification according to risk score and predicted survival rate. Based on review by lymphoma pathology experts, we enrolled 198 patients diagnosed with Tfh cell lymphoma in this retrospective study. AITL was the most common subtype (n = 168), followed by F-PTCL (n = 21) and nodal PTCL with Tfh cell phenotype (n = 9). The median progression-free survival and overall survival with front-line treatment was 0.8 years (95% confidence interval [CI], 0.6-1.1 years) and 2.9 years (95% CI, 1.6-4.2 years), respectively. The AITL score showed better differentiation than other scoring systems in terms of classification according to risk score. However, for predicting PFS (concordance-index [C-index], IPI vs. PIT vs. modified PIT vs. international T-cell lymphoma project index vs. AITL score; 0.617 vs. 0.605 vs. 0.576 vs. 0.591 vs. 0.592) and OS (C-index, IPI vs. PIT vs. modified PIT vs. international T-cell lymphoma project index vs. AITL score; 0.663 vs. 0.651 vs. 0.612 vs. 0.672 vs. 0.583), the IPI, and the international T-cell lymphoma project index showed better performance. In conclusion, there are unmet needs to develop a prognostic index for Tfh cell lymphoma because its characteristics differ from PTCL-NOS. Although the AITL score reflects Tfh cell-origin lymphoma characteristics well and clearly shows their power of classification according to risk score, there are concerns about accurate prediction of survival outcomes. Therefore, it seems too early to settle on a single scoring system in Tfh cell origin lymphoma. In the future, along with classification, a more effective tool for survival prediction needs to be developed that reflects the specific characteristics of T-cell lymphoma.
    MeSH term(s) Humans ; Immunoblastic Lymphadenopathy/diagnosis ; Immunoblastic Lymphadenopathy/pathology ; Lymphoma, T-Cell/pathology ; Lymphoma, T-Cell, Peripheral ; Prognosis ; Retrospective Studies
    Language English
    Publishing date 2022-05-31
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 1064950-5
    ISSN 1432-0584 ; 0939-5555 ; 0945-8077
    ISSN (online) 1432-0584
    ISSN 0939-5555 ; 0945-8077
    DOI 10.1007/s00277-022-04805-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Di-indenopyridines as topoisomerase II-selective anticancer agents: Design, synthesis, and structure-activity relationships.

    Shrestha, Aarajana / Hwang, Soo-Yeon / Kunwar, Surendra / Man Kadayat, Tara / Park, Seojeong / Liu, Yi / Jo, Hyunji / Sheen, Naeun / Seo, Minjung / Lee, Eung-Seok / Kwon, Youngjoo

    Bioorganic & medicinal chemistry

    2023  Volume 91, Page(s) 117403

    Abstract: Topoisomerases are key molecular enzymes responsible for altering DNA topology, thus they have long been considered as attractive targets for novel chemotherapeutic agents. Topoisomerase type II (Topo II) catalytic inhibitors embrace a fresh perspective ... ...

    Abstract Topoisomerases are key molecular enzymes responsible for altering DNA topology, thus they have long been considered as attractive targets for novel chemotherapeutic agents. Topoisomerase type II (Topo II) catalytic inhibitors embrace a fresh perspective meant to get beyond drawbacks caused by topo II poisons, such as cardiotoxicity and secondary malignancies. Based on previously reported 5H-indeno[1,2-b]pyridines, here we presented new twenty-three hybrid di-indenopyridines along with their topo I/IIα inhibitory and antiproliferative activity. Most of the prepared 11-phenyl-diindenopyridines showed negligible topo I inhibitory activity, showing selectivity over topo II. Among the series, we finally selected compound 17, which displayed 100 % topo IIα inhibition at 20 μM concentration and comparable antiproliferative activity against the tested cell lines. Through competitive EtBr displacement assay, cleavable complex assay, and comet assay, compound 17 was finally determined as a non-intercalative catalytic topo IIα inhibitor. The findings in this study highlight the significance of phenolic, halophenyl, thienyl, and furyl groups at the 4-position of the indane ring in the design and synthesis of di-indenopyridines as potent catalytic topo IIα inhibitors with remarkable anticancer effects.
    MeSH term(s) Cell Line, Tumor ; Structure-Activity Relationship ; Antineoplastic Agents ; Topoisomerase II Inhibitors ; DNA Topoisomerases, Type II/metabolism ; Cell Proliferation
    Chemical Substances compound 17 (31122-84-6) ; Antineoplastic Agents ; Topoisomerase II Inhibitors ; DNA Topoisomerases, Type II (EC 5.99.1.3)
    Language English
    Publishing date 2023-07-04
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1161284-8
    ISSN 1464-3391 ; 0968-0896
    ISSN (online) 1464-3391
    ISSN 0968-0896
    DOI 10.1016/j.bmc.2023.117403
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: A chromenone analog as an ATP-competitive, DNA non-intercalative topoisomerase II catalytic inhibitor with preferences toward the alpha isoform

    Park, Seojeong / Hwang, Soo-Yeon / Jo, Hyunji / Kwon, Youngjoo / Na, Younghwa / Shin, Jaeho

    Chemical communications. 2019 Oct. 22, v. 55, no. 85

    2019  

    Abstract: 5-Hydroxy-2-phenyl-7-(thiiran-2-ylmethoxy)-4H-chromen-4-one (compound 52) was found as a DNA non-intercalative topo II specific catalytic inhibitor by targeting its ATP-binding domain. Showing changes in interaction with Mg2+, it exhibited highly ... ...

    Abstract 5-Hydroxy-2-phenyl-7-(thiiran-2-ylmethoxy)-4H-chromen-4-one (compound 52) was found as a DNA non-intercalative topo II specific catalytic inhibitor by targeting its ATP-binding domain. Showing changes in interaction with Mg2+, it exhibited highly selective properties against the α-isoform with less toxicity, unlike other topo II poisons, such as etoposide.
    Keywords ABC transporters ; catalytic activity ; chemical reactions ; DNA ; DNA topoisomerase (ATP-hydrolysing) ; etoposide ; magnesium ; toxicity
    Language English
    Dates of publication 2019-1022
    Size p. 12857-12860.
    Publishing place The Royal Society of Chemistry
    Document type Article
    ZDB-ID 1472881-3
    ISSN 1364-548X ; 1359-7345 ; 0009-241X
    ISSN (online) 1364-548X
    ISSN 1359-7345 ; 0009-241X
    DOI 10.1039/c9cc05524j
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  8. Article ; Online: Design, synthesis, and structure-activity relationships of new benzofuro[3,2-b]pyridin-7-ols as DNA topoisomerase II inhibitors.

    Shrestha, Aarajana / Jo, Hyunji / Kwon, Youngjoo / Lee, Eung-Seok

    Bioorganic & medicinal chemistry letters

    2018  Volume 28, Issue 4, Page(s) 566–571

    Abstract: Human DNA topoisomerases have become attractive targets for developing more effective anticancer drugs. In this study, a series of new benzofuro[3,2-b]pyridin-7-ols were designed and synthesized for the first time and screened for their topoisomerase I ... ...

    Abstract Human DNA topoisomerases have become attractive targets for developing more effective anticancer drugs. In this study, a series of new benzofuro[3,2-b]pyridin-7-ols were designed and synthesized for the first time and screened for their topoisomerase I and II inhibitory and antiproliferative activity. Structure-activity relationships revealed the position of ortho- and para-hydroxyl group at 2-phenyl ring, and meta-hydroxyl group at 4-phenyl ring of benzofuro[3,2-b]pyridin-7-ol are important for potent and selective topo II inhibitory activity. Compound 11 showed the most selective and potent topo II inhibition (100% inhibition at 100 µM) and strongest antiproliferative activity (IC
    MeSH term(s) Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Antineoplastic Agents/pharmacology ; Benzofurans/chemical synthesis ; Benzofurans/chemistry ; Benzofurans/pharmacology ; Cell Line, Tumor ; Cell Proliferation/drug effects ; DNA Topoisomerases, Type I/metabolism ; Drug Design ; Drug Screening Assays, Antitumor ; Etoposide/pharmacology ; Humans ; Molecular Structure ; Pyridines/chemical synthesis ; Pyridines/chemistry ; Pyridines/pharmacology ; Structure-Activity Relationship ; Topoisomerase I Inhibitors/chemical synthesis ; Topoisomerase I Inhibitors/chemistry ; Topoisomerase I Inhibitors/pharmacology ; Topoisomerase II Inhibitors/chemical synthesis ; Topoisomerase II Inhibitors/chemistry ; Topoisomerase II Inhibitors/pharmacology
    Chemical Substances Antineoplastic Agents ; Benzofurans ; Pyridines ; Topoisomerase I Inhibitors ; Topoisomerase II Inhibitors ; Etoposide (6PLQ3CP4P3) ; DNA Topoisomerases, Type I (EC 5.99.1.2) ; TOP1 protein, human (EC 5.99.1.2)
    Language English
    Publishing date 2018-02-03
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1063195-1
    ISSN 1464-3405 ; 0960-894X
    ISSN (online) 1464-3405
    ISSN 0960-894X
    DOI 10.1016/j.bmcl.2018.01.048
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: The synthesis and anticancer activities of chiral epoxy-substituted chromone analogs.

    Jo, Hyunji / Hee Seo, Seung / Na, Younghwa / Kwon, Youngjoo

    Bioorganic chemistry

    2018  Volume 84, Page(s) 347–354

    Abstract: Human DNA topoisomerases (topos) have been recognized as a good target molecule for the development of anticancer drugs because they play an important role in solving DNA topological problems caused by DNA strand separation during replication and ... ...

    Abstract Human DNA topoisomerases (topos) have been recognized as a good target molecule for the development of anticancer drugs because they play an important role in solving DNA topological problems caused by DNA strand separation during replication and transcription. In this study, we designed and synthesized 11 novel chromone backbone compounds possessing epoxy and halohydrin substituents with chirality. In the topos inhibition test, compounds 2, 9, 10, and 11 showed comparable topo I inhibitory activity at concentration of 100 μM compared to camptothecin, and all of the synthesized compounds showed moderate topo IIα inhibitory activity. Among them, compounds 9, 10 and 11 were more potent than the others in both topo I and IIα inhibitory activity. Compound 11 showed the most potent cell antiproliferative activity against all tested cancer cell lines with particularly strong inhibition (an IC
    MeSH term(s) Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/pharmacology ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Chromones/chemistry ; Chromones/pharmacology ; DNA Topoisomerases, Type I/chemistry ; DNA Topoisomerases, Type I/metabolism ; DNA Topoisomerases, Type II/chemistry ; DNA Topoisomerases, Type II/metabolism ; G2 Phase Cell Cycle Checkpoints/drug effects ; Humans ; M Phase Cell Cycle Checkpoints/drug effects ; Stereoisomerism ; Structure-Activity Relationship ; Topoisomerase II Inhibitors/chemical synthesis ; Topoisomerase II Inhibitors/metabolism ; Topoisomerase II Inhibitors/pharmacology
    Chemical Substances Antineoplastic Agents ; Chromones ; Topoisomerase II Inhibitors ; DNA Topoisomerases, Type I (EC 5.99.1.2) ; DNA Topoisomerases, Type II (EC 5.99.1.3)
    Language English
    Publishing date 2018-11-30
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 120080-x
    ISSN 1090-2120 ; 0045-2068
    ISSN (online) 1090-2120
    ISSN 0045-2068
    DOI 10.1016/j.bioorg.2018.11.054
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers.

    Kim, Hye Ryeon / Ahn, Soomin / Jo, Hyunji / Kim, Hongsik / Hong, Joohyun / Lee, Jeeyun / Lim, Ho-Yeong / Kang, Won Ki / Kim, Seung Tae

    Frontiers in oncology

    2021  Volume 11, Page(s) 792340

    Abstract: Background: Trastuzumab is a HER2-trargeted humanized monoclonal antibody that has been studied as a first-line treatment for patients with HER2-positive advanced gastric cancer (AGC). The effect of anti-HER2 therapy according to tumor mutational burden ...

    Abstract Background: Trastuzumab is a HER2-trargeted humanized monoclonal antibody that has been studied as a first-line treatment for patients with HER2-positive advanced gastric cancer (AGC). The effect of anti-HER2 therapy according to tumor mutational burden (TMB) in HER2-positive AGC remains unclear.
    Methods: We performed next-generation sequencing (NGS), including TMB analysis, in 31 HER2-positive AGC patients with trastuzumab plus chemotherapy as first-line therapy for recurrent (n=8) or metastatic (n=23) tumors. The TruSight Oncology 500 Assay from Illumina (San Diego, CA, USA) was used to evaluate TMB.
    Results: Among 31 patients, 30 had tumors with immunohistochemistry (IHC) 3+, and one was IHC 2+ and silver
    Conclusion: The status of TMB could be a novel biomarker in predicting the efficacy of trastuzumab plus chemotherapy in HER2-positive AGCs.
    Language English
    Publishing date 2021-12-02
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2021.792340
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top